09/736,051
Hua Zhu Ke
David O. Thompson
Actual Filing: 12/13/2000
Earliest effective: 2/26/1996

AMENDMENTS TO THE CLAIMS

1. (original) A pharmaceutical composition comprising:
   a. a therapeutically effective amount of a first compound, said first compound being an estrogen agonist/antagonist; and
   b. a therapeutically effective amount of a second compound, said second compound being a prostaglandin or a prostaglandin agonist/antagonist.
2. (original) A pharmaceutical composition as recited in claim 1 additionally comprising a pharmaceutical carrier. 82413-20-5 84449-90-1 105540-29-1 68047-06-3
3. (original) A pharmaceutical composition as recited in claim 2 wherein the estrogen agonist/antagonist is (1) droloxifene, (2) raloxifene, (3) tamoxifen, (4) 4-hydroxy-tamoxifen, (5) *Cis*-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8 tetrahydro-naphthalene-2-ol; 180915-84-8 (6) (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; 180915-78-0 (7) *Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; 180916-16-9 (8) *Cis*-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene; 193274-89-4 (9) 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; 180916-14-7 (10) *Cis*-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or 180915-86-0 (11) 1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline. 180916-15-8 bone loss
4. (original) A pharmaceutical composition according to claim 3 wherein the second compound is PGD_1, PGD_2, PGE_2, PGE_1, PGF_2, $PGF_2\alpha$ or 3S-(3-Hydroxy-4-phenyl-butyl)-2R-[6-(1H-tetrazol-5-yl)-hexyl]-cyclopentanone. (12) 195-962-24-4 bone loss
5. (canceled)
6. (previously presented) A pharmaceutical composition according to claim 4 wherein the second compound is PGE_2.
7. (previously presented) A pharmaceutical composition according to claim 4 wherein the second compound is 3S-(3-Hydroxy-4-phenyl-butyl)-2R-[6-(2H-tetrazol-5-yl)-hexyl]-cyclopentanone.

8. (original) A pharmaceutical composition according to claim 4 wherein the estrogen agonist/antagonist is

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

(-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline.

9. (original) A pharmaceutical composition according to claim 8 wherein the second compound is PGE_2.

10. (original) A pharmaceutical composition according to claim 8 wherein the second compound is 3S-(3-Hydroxy-4-phenyl-butyl)-2R-[6-(2H-tetrazol-5-yl)-hexyl]-cyclopentanone.

11. (original) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

a. a therapeutically effective amount of a first compound, said first compound being an estrogen agonist/antagonist; and

b. a therapeutically effective amount of a second compound, said second compound being a prostaglandin or a prostaglandin agonist/antagonist.

12. (original) A method as recited in claim 11 wherein the estrogen agonist/antagonist is droloxifene, raloxifene, tamoxifen, 4-hydroxy-tamoxifen, idoxifene, centrachroman,

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

(-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;